{"entity":{"id":"nct03899792","kind":"trial","name":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","aka":["LIBRETTO-121"],"tldr":"A phase 1/2 trial of Selpercatinib in thyroid cancer and sarcomas, run by Eli Lilly and Company, active and no longer recruiting.","summary":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors is a phase 1/2 interventional study registered as NCT03899792 by Eli Lilly and Company, with 36 participants enrolled, started 2019-06-13 and due to reach its primary completion in 2024-11-08. Interventions recorded: Selpercatinib. Conditions listed: Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03899792","url":"https://clinicaltrials.gov/study/NCT03899792"}],"tags":["ctgov-ingest"],"related":[],"cancers":["thyroid","sarcoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["selpercatinib"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03899792","phase":"1/2","setting":"A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors","sponsor":"Eli Lilly and Company","started":"2019-06-13","startedType":"actual","yearReported":2026,"enrolled":36,"enrolledBasis":"registry","outcomes":[{"endpoint":"Phase 2: Percentage of Participants With Overall Response Rate (ORR) in Study","primary":true,"unit":"%","arms":[{"name":"Cohort 1 (Phase 2): MTC Group","n":15,"value":60,"note":"Figures from the ClinicalTrials.gov results section (first posted 2026-01-06), not from a publication"},{"name":"Cohort 2 (Phase 2): PTC Group","n":15,"value":53.3},{"name":"Cohort 3 (Phase 2): Other Cancer Group","n":6,"value":33.3}],"source":"https://clinicaltrials.gov/study/NCT03899792?tab=results"}]},"route":"/trials/nct03899792/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}